Description: Founded in 2008, GreenLight aims to address some of the world's biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company's breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight's human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review.
Home Page: greenlightbiosciences.com
GRNA Technical Analysis
200 Boston Avenue
Medford,
MA
02155
United States
Phone:
617 616 8188
Officers
| Name | Title |
|---|---|
| Dr. Andrey Juan Zarur Ph.D. | Co-Founder, Pres, CEO & Director |
| Ms. Susan E. Keefe M.B.A. | CFO & Interim Chief Accounting Officer |
| Ms. Carole Beth Cobb M.B.A. | Chief Operating Officer |
| Ms. Marta Ortega-Valle M.B.A., M.Sc. | Co-Founder & Chief Bus. Officer of Human Health |
| Dr. Drew Cunningham Ph.D. | Chief Technology Officer |
| Mr. David D. Kennedy Esq. | Gen. Counsel & Corp. Sec. |
| Ms. Charu Manocha M.B.A. | Chief People Officer |
| Mr. Thomas Crampton | Sr. VP & Head of Corp. Affairs |
| Dr. Mark T. Singleton Ph.D. | Chief Commercial Officer & Gen. Mang. of Plant Health |
| Dr. Amin Khan Ph.D. | Chief Science Officer of Human Health |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1364 |
| Price-to-Sales TTM: | 41.4116 |
| IPO Date: | 2022-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |